Pfizer Stock News

Pfizer and BioNTech asked a London court to revoke rival Moderna's patents over technology key to the development of vaccines for COVID-19, as the latest leg of a global legal battle began on Tuesday.

Pfizer (PFE) reachead $26.26 at the closing of the latest trading day, reflecting a +1% change compared to its last close.

It's an established point that blue-chip stocks are an essential part of the portfolio. The exposure to blue-chips can differ based on the risk-taking ability of an investor.

Enterprise Products Partners offers an ultra-high distribution yield plus solid growth prospects. Intel could roar back with a massive AI tailwind.

Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.

Take the quiz below to get matched with a financial advisor today. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.

Since my last article, the company's share price has fallen about 10% despite its quarterly revenue growth and achieving significant success in developing experimental drugs. In addition to growing sa

Today, I will present you with two attractive high dividend yield companies that can help to enhance your dividend income. I have added both companies to The Dividend Income Accelerator Portfolio. Thi

Pfizer's stock has been a disappointment in recent times due to a number of factors. This includes a decline in Covid cases as well as looming patent protection expirations.

The markets declined for the second consecutive week, causing a retracement in the Dividend Harvesting Portfolio. Dividend income generated in week 163 was light, but the portfolio's forward projected

Hidden treasures sometimes go overlooked in the busy world of financial markets. Here, attention is frequently drawn to the names with the most sparkle.

On April 1, 2024, Barron's, Bloomberg, and Kiplinger analysts listed four sets of stocks here-named ProActive for 2024. Those four articles revealed 28 equities, with 24 paying-dividends. The four Pro

Since Wall Street's major stock indexes tend to rise over the long run, anytime can be the ideal time to put money to work. Most online brokers have done away with minimum deposit requirements and com

A couple of big-picture trends in biotech could add up to a nice investment opportunity. First, corporate buyouts are back in style.

PFE's dividend has reached the sky-high (for a biotech) ~6% mark. Are the dividend and recent share price decline enough to make PFE an attractive play? PFE is following a similar trajectory to GILD i